Influence of miR‑101 on proliferation of liver cancer cells through the MAPK/ERK signaling pathway

Meng,Xuan; Shi,Yong; Xiang,Xin; Li,Chonghui; Ge,Xinlan; Pan,Ke; Liang,Yurong

doi:10.3892/ol.2019.11210

Influence of miR‑101 on proliferation of liver cancer cells through the MAPK/ERK signaling pathway

Authors:
- Xuan Meng
- Yong Shi
- Xin Xiang
- Chonghui Li
- Xinlan Ge
- Ke Pan
- Yurong Liang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: December 12, 2019 https://doi.org/10.3892/ol.2019.11210
Pages: 1310-1316
Copyright : © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of miR‑101 in carcinoma and para‑carcinoma tissues of patients with liver cancer was studied. The carcinoma and para‑carcinoma tissues of 67 patients with liver cancer treated in Chinese PLA General Hospital were collected, and the expression of miR‑101 in carcinoma and para‑carcinoma tissues was detected via reverse transcription‑polymerase chain reaction (RT-PCR). The liver cancer HepG2 cell line was transfected with miR‑101 mimics. Moreover, the influence of miR‑101 overexpression on the proliferation of liver cancer cells was detected via Cell Counting Kit‑8 assay and colony formation assay. The proportion of Ki67‑positive cells in the control group (NC group) and miR‑101 overexpression group (miR‑101 mimics group) was detected via Ki67 staining. The proportions of cells were detected via flow cytometry, and the predicted target gene Zeste2 enhancer (EZH2) was further verified via luciferase reporter gene assay and western blotting. The miR‑101 overexpression significantly inhibited the colony formation and proliferation ability of liver cancer cells (P<0.05). The proportion of Ki67‑positive cells in liver cancer cells was lower in miR‑101 mimics group (P<0.05). The proportion of cells in G0/G1 phase was increased in miR‑101 mimics group compared with that in NC group (P<0.05). The extracellular signal‑regulated kinase (ERK)1/2 phosphorylation level in liver cancer cells was obviously suppressed in miR‑101 mimics group (P<0.05). Therefore, the expression level of miR‑101 declines in liver cancer tissues, and the miR‑101 overexpression can inhibit the proliferation of liver cancer cells. The inhibitory effect of miR‑101 on the proliferation of liver cancer cells may be related to its inhibition on the mitogen‑activated protein kinase (MAPK)/ERK signaling pathway, and the inhibition on the MAPK/ERK may be mediated by the targeted inhibition of miR‑101 on EZH2.

View Figures

View References

1	Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Schicho R, Fickert P, et al: New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 83:56–70. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zhang H, Song Y, Yang H, Liu Z, Gao L, Liang X and Ma C: Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis. Oncogene. 37:2456–2468. 2018. View Article : Google Scholar : PubMed/NCBI
3	Maucort-Boulch D, de Martel C, Franceschi S and Plummer M: Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 142:2471–2477. 2018. View Article : Google Scholar : PubMed/NCBI
4	Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, Hu GY, Dong P, Bai FZ, Yan XL, Liao XZ, et al: Medical expenditure for liver cancer in urban China: A 10-year multicenter retrospective survey (2002–2011). J Cancer Res Ther. 14:163–170. 2018. View Article : Google Scholar : PubMed/NCBI
5	Gao SB, Li KL, Qiu H, Zhu LY, Pan CB, Zhao Y, Wei SH, Shi S, Jin GH and Xue LX: Enhancing chemotherapy sensitivity by targeting PcG via the ATM/p53 pathway. Am J Cancer Res. 7:1874–1883. 2017.PubMed/NCBI
6	Laugesen A, Højfeldt JW and Helin K: Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer. Cold Spring Harb Perspect Med. 6:62016. View Article : Google Scholar
7	Hu G, Gupta SK, Troska TP, Nair A and Gupta M: Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget. 8:80223–80234. 2017.PubMed/NCBI
8	Yoshida K, Toden S, Ravindranathan P, Han H and Goel A: Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Carcinogenesis. 38:1036–1046. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, et al: Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Mol Cell. 69:279–291.e5. 2018. View Article : Google Scholar : PubMed/NCBI
10	Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 1:710–720. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
12	Naga Prasad SV, Gupta MK, Duan ZH, Surampudi VS, Liu CG, Kotwal A, Moravec CS, Starling RC, Perez DM, Sen S, et al: A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. PLoS One. 12:e01704562017. View Article : Google Scholar : PubMed/NCBI
13	Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA and Bray F: Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 67:600–611. 2018. View Article : Google Scholar : PubMed/NCBI
14	Fang CH, Lu CM, Huang YP, Li XF, Fan YF, Yang J, Xiang N and Pan JH: Study on the application value of digital medical technology in the operation on primary liver cancer. Zhonghua Wai Ke Za Zhi. 47:523–526. 2009.(In Chinese). PubMed/NCBI
15	Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, Leung C, Wang HH, Wong GL, Wong VW, et al: International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 7:458462017. View Article : Google Scholar : PubMed/NCBI
16	Thomson DW and Dinger ME: Endogenous microRNA sponges: Evidence and controversy. Nat Rev Genet. 17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011. View Article : Google Scholar : PubMed/NCBI
18	Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z and Liu X: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer. 13:4692013. View Article : Google Scholar : PubMed/NCBI
19	Yu Q, Yang X, Duan W, Li C, Luo Y and Lu S: miRNA-346 promotes proliferation, migration and invasion in liver cancer. Oncol Lett. 14:3255–3260. 2017. View Article : Google Scholar : PubMed/NCBI
20	Kim KH and Roberts CW: Targeting EZH2 in cancer. Nat Med. 22:128–134. 2016. View Article : Google Scholar : PubMed/NCBI
21	Cardenas H, Zhao J, Vieth E, Nephew KP and Matei D: EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget. 7:84453–84467. 2016. View Article : Google Scholar : PubMed/NCBI
22	Huang D, Wang X, Zhuang C, Shi W, Liu M, Tu Q, Zhang D and Hu L: Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma. Oncol Rep. 35:1083–1090. 2016. View Article : Google Scholar : PubMed/NCBI
23	Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC and Tsichlis PN: FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 43:285–298. 2011. View Article : Google Scholar : PubMed/NCBI
24	Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D and Eichmüller SB: MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett. 341:240–247. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhang JJ, Chen JT, Hua L, Yao KH and Wang CY: miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway. Biomed Pharmacother. 85:472–478. 2017. View Article : Google Scholar : PubMed/NCBI